Delta-Fly Pharma, Inc. (TYO:4598)
Japan flag Japan · Delayed Price · Currency is JPY
56.00
-2.00 (-3.45%)
Nov 18, 2026, 1:07 PM JST

Delta-Fly Pharma Income Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
-----300
Revenue Growth
-----0%
Gross Profit
-----300
Selling, General & Admin
177210212229261287
Research & Development
1,3261,3291,4371,1181,011940
Other Operating Expenses
666659564334
Operating Expenses
1,5691,6051,7081,4031,3151,261
Operating Income
-1,569-1,605-1,708-1,403-1,315-961
Currency Exchange Gain (Loss)
---1-5-5-
Other Non Operating Income (Expenses)
-16-18-10-19-5-3
Pretax Income
-1,585-1,623-1,719-1,427-1,325-964
Income Tax Expense
122233
Net Income
-1,586-1,625-1,721-1,429-1,328-967
Net Income to Common
-1,586-1,625-1,721-1,429-1,328-967
Net Income Growth
------
Shares Outstanding (Basic)
14129765
Shares Outstanding (Diluted)
14129765
Shares Change
33.57%31.55%22.38%26.91%4.61%17.64%
EPS (Basic)
-117.00-140.37-195.56-198.72-234.37-178.52
EPS (Diluted)
-117.00-140.37-195.56-198.72-234.37-178.52
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
--1,557-1,834-1,280-1,303-940
Free Cash Flow Per Share
--134.50-208.41-178.00-229.96-173.54
Gross Margin
-----100.00%
Operating Margin
------320.33%
Profit Margin
------322.33%
Free Cash Flow Margin
------313.33%
EBITDA
-1,568-1,604-1,707-1,402-1,314-960
D&A For EBITDA
111111
EBIT
-1,569-1,605-1,708-1,403-1,315-961